News
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth company less than two months after it started.
Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Hims wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight-loss medicine, said ...
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...
Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...
Zacks.com on MSN2h
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?Hims & Hers Health (HIMS) has been one of the market’s standout growth stocks in recent years. The company has successfully ...
Energy stocks posted declines after the [U.S. attacked Iranian nuclear facilities](http ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback